Titan Biotech share price

Titan Biotech Ltd's share price was ₹399.35 at the close on 18 August 2026. It has been rising for 49 weeks. That is 15.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹89 and ₹504, and at that close it sat 75% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Titan Biotech Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row.

Over the last 10 years the share price moved +5,162% while the NIFTY 500 moved +277%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: best operating margin in 10 quarters, highest quarterly profit in 15 quarters and revenue up on a year earlier for 5 quarters in a row.

1. Best operating margin in 10 quarters

   Operating margin was 21% in the June 2026 quarter, against 19% a year earlier.

2. Highest quarterly profit in 15 quarters

   Profit of ₹11 crore in the June 2026 quarter is the highest of the last 15 quarters.

3. Revenue up on a year earlier for 5 quarters in a row

   In the June 2026 quarter revenue was ₹59 crore, +28.3% on a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Titan Biotech reported revenue of ₹59.0 crore, up 28.3% from ₹46.0 crore a year earlier, and a profit of ₹11.0 crore, up 57.1% from ₹7.00 crore.

Titan Biotech results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Titan Biotech closed at ₹399.35 on 18 August 2026, up 323.8% from ₹94.22 a year earlier (14 August 2025) and up 497.8% over five years. Its highest weekly close since March 2016 was ₹424.85 on 17 July 2026.

Titan Biotech share price: then and now

Weekly closing prices. Each change is the move from that price to the 18 Aug 2026 close. A day's intraday high or low can go beyond these weekly closes.

530 weekly closes from 11 March 2016 to 18 August 2026.

18 Aug 2026: Titan Biotech closed at ₹399.35, down 2.9% on the week and down 6.0% on the month. Results for April to June 2026: Revenue up 28.3% and profit up 57.1% on a year earlier.

The NSE corporate-actions record has no dividend for Titan Biotech since 1 April 2021, so this page cannot show amounts per share.

Yes. Titan Biotech Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 12 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Titan Biotech is not on any of our India lists this week.

Titan Biotech Ltd earned ₹11.0 Cr of net profit in the Jun 2026 quarter, +57.1% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹30.0 Cr. Over 10 years profit has grown 31.1% a year on average. That is 18.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹7.0 Cr.

For the full year, FY26 profit was ₹30.0 Cr (+36.4% on the year before).

Why profit moved: revenue changed +28.3% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +67.9% and revenue +38.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Titan Biotech Ltd reported ₹59.0 Cr of revenue in the Jun 2026 quarter, +28.3% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 16.2% a year on average. The last full year, FY26, came in at ₹206 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹219 Cr.

FY26 revenue was ₹206 Cr, +32.1% on the year before.

Recent pace: the last four quarters grew +38.3% on average, against 16.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +37.7%, against +12.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +59.1%, against +18.3% a year (accelerating).

Titan Biotech Ltd's operating margin was 21.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Across 12 years it has been between 9.0% and 32.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +4.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 92% of Titan Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹30.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹10.0 Cr of spending on assets, ₹20.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 92% of profit came in as cash: the cash cycle got 17 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building.

Titan Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 220 days in FY26, up from 203 days in FY21. It spent ₹27.0 Cr on assets over the last 3 years. Customers take 40 days to pay, and stock sits for 212 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹206 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹124 Cr is tied up in the business at any time.

FY26: customers took 40 days to pay and stock sat for 212 days, about 7.0 months of sales sitting as stock, for a full cycle of 220 days, longer than FY21's 203.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 212 days. Customers pay about 40 days after that. Suppliers are paid at 32 days. Together that makes the 220-day cycle.

Spending on assets: ₹27.0 Cr over the last 3 years, against ₹12.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Titan Biotech Ltd's P/E is 48.7×, near the high end of its own history: higher than 96% of past readings. Its usual P/E (the middle reading) is 12.6×, over 9.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +38.8% while the price moved +323.8%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +43.0% a year; about +5.0% a year came from earnings growth and about +38.0 percentage points from the multiple (the market paying more); over 10 years the price moved +49.4% a year; about +33.4% a year came from earnings growth and about +16.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Worked out from its price on 13 June 2026, Titan Biotech Ltd's share price assumed profit growth of about 23.9% a year. Over the past 10 years its profit actually grew 31.1% a year. Today its P/E is 48.7×, higher than 96% of its own last 9.9 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 18 August 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Titan Biotech Ltd's business is turning around. Profit growth has swung from −12.0% at its low to +59.1%, improving for 4 quarters in a row, with ROCE steady at 23.0%. This is based on 8 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.